Maxim Group analyst Jason McCarthy reiterated a Buy rating on TriSalus Life Sciences (TLSI – Research Report) yesterday and set a price target of $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors including TriSalus Life Sciences’ strong financial performance and strategic decisions. The company reported impressive first-quarter results with TriNav system sales surpassing expectations, showing a significant year-over-year and quarter-over-quarter growth. This growth is supported by expanded product offerings and improved reimbursement codes, with the company maintaining a robust outlook for continued revenue growth in 2025.
Additionally, TriSalus is strategically winding down its development of the TLR9 agonist nelitolimod, aiming to partner the asset and focus on its commercial business, which is a prudent move to conserve capital. The company’s efforts to improve its capital structure through preferred stock conversion and a successful private placement further strengthen its financial position. These factors, combined with the expectation of achieving profitability by early 2026, underpin McCarthy’s positive outlook and Buy rating for TriSalus Life Sciences.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Actinium Pharmaceuticals, and Gain Therapeutics. According to TipRanks, McCarthy has an average return of -21.7% and a 26.41% success rate on recommended stocks.
In another report released today, Lake Street also reiterated a Buy rating on the stock with a $10.00 price target.